Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Clinical trial NCT01472627 · COMPLETED
Trial details
- NCT number
- NCT01472627
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2010-10-01
- Primary completion
- 2018-01-01
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.